Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy.

Xuanmao JiaoMin WangZhao ZhangZhiping LiDong NiAnthony W AshtonHsin-Yao TangDavid W SpeicherRichard G Pestell

Published in: Breast cancer research : BCR (2021)

The safety profile of leronlimab, together with strong preclinical evidence to both prevent and reduce established breast cancer metastasis herein, suggests studies of clinical efficacy may be warranted.

Keyphrases

monoclonal antibody
cell death
circulating tumor
single molecule
cell free
young adults
cell cycle arrest
bone marrow
signaling pathway
cell proliferation